1. Home
  2. Labeler Index
  3. Marlex Pharmaceuticals, Inc.
  4. 10135-718
  5. Product Images: Alendronate

Product Images Alendronate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 12 images provide visual information about the product associated with Alendronate NDC 10135-718 by Marlex Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Alendronate-35mg-3x4 - Alendronalte 35mg 3x4

Alendronate-35mg-3x4 - Alendronalte 35mg 3x4

Alendronate-35mg-4 - Alendronate 35mg 4

Alendronate-35mg-4 - Alendronate 35mg 4

Alendronate-70mg-2x10 - Alendronate 70mg 2x10

Alendronate-70mg-2x10 - Alendronate 70mg 2x10

Alendronate-70mg-3x4 - Alendronate 70mg 3x4

Alendronate-70mg-3x4 - Alendronate 70mg 3x4

Alendronate-70mg-4 - Alendronate 70mg 4

Alendronate-70mg-4 - Alendronate 70mg 4

figure 2 - Figure 2

figure 2 - Figure 2

figure 1 - figure 1

figure 1 - figure 1

figure 3 - figure 3

figure 3 - figure 3

This appears to be a table or graph showing data for two studies comparing the effects of Alendronate Sodium 10 mg (a medication used to treat or prevent osteoporosis) versus a placebo on bone mineral density (BMD) over a period of 36 months. The data is presented as mean percent change from baseline, and there are separate results displayed for a US study and a multinational study. The table/graph also shows the time points at which the BMD measurements were taken (0, 12, 24, and 36 months).*

figure 4 - figure 4

figure 4 - figure 4

figure 5 - figure 5

figure 5 - figure 5

The text provides a figure numbered as 5, which indicates an increase in BMD (Bone Mineral Density) in glucocorticoid-treated patients. The text further mentions the dosage of Alendronates administered per day for one year as the treatment. The increase in BMD is represented as a mean of 9% relative to placebo + SE. The figure possibly indicates the increase in BMD at the Lumbar Spine, Femoral Neck, and Trochanter.*

figure 6 - figure 6

figure 6 - figure 6

This is a graph showing the effect of Alendronate 40 mg/day versus placebo or Etidronate 400 mg/day on Serum Alkaline Phosphatase in Stu Paget's Disease of Bone over time in months.*

structure - structure

structure - structure

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.